Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rasburicase to Prevent Graft -Versus-Host Disease

NCT00513474 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00513474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00513474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rasburicase to Prevent Graft -Versus-Host Disease
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2008
Completion date
February 12, 2013
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloproliferative disorders, graft versus host disease, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasms